Endometrial carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 20, Issue SUPPL. 4, 2009, Pages

  Baekelandt, M M ^a   Castiglione, M ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CISPLATIN; GESTAGEN; PACLITAXEL;

ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; ENDOMETRIUM CARCINOMA; EUROPEAN UNION; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; INCIDENCE; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; LYMPH NODE DISSECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY;

ENDOMETRIAL NEOPLASMS; EUROPE; FEMALE; FOLLOW-UP STUDIES; HEALTH PLANNING GUIDELINES; HUMANS; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 66549093573     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp120     Document Type: Article

References (13)

1. Kinkel K, Kaji Y, Yu KK et al. Radiologic staging in patients with endometrial cancer: A meta-analysis. Radiology 1999; 212: 711-718.
2. Chan JK, Wu H, Cheung MK et al. The outcomes of 27 063 women with unstaged endometrioid uterine cancer. Gynecol Oncol 2007; 106: 282-288.
3. Frumovitz M, Singh DK, Meyer L et al. Predictors of final histology in patients with endometrial cancer. Gynecol Oncol 2004; 95: 463-468.
4. Chan JK, Urban R, Cheung MK et al. Lymphadenectomy in endometrioid uterine cancer staging: How many lymph nodes are enough? A study of 11 433 patients. Cancer 2007; 109: 2454-2460.
5. Mariani A, Webb MJ, Keeney GL et al. Low-risk corpus cancer: Is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol 2000; 182: 1506-1519.
6. Scholten AN, van Putten WLJ, Beerman H et al. Postoperative radiotherapy for stage 1 endometrial carcinoma: Long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiation Oncology Biol Phys 2005; 63: 834-838.
7. Lukka H, Chambers A, Fyles A et al. Adjuvant radiotherapy in women with stage I endometrial cancer: A systematic review. Gynecol Oncol 2006; 102: 361-368.
8. Høgberg T, Rosenberg P, Kristensen G et al. A randomized phase III study on adjuvant treatment with radiation ± chemotherapy in early stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991). J Clin Oncol 2007; 25(18S): Abstr 5503.
9. Martin-Hirsch PPL, Jarvis GG, Kitchener HC. Lilford. Progestagens for endometrial cancer (Cochrane review). Cochrane Database Syst Rev 1999 (Issue 4); CD001040.
10. Lambrou NC, Gómez-Marín O, Mirhashemi R et al. Optimal surgical cytoreduction in patients with stage III and stage IV endometrial carcinoma: A study of morbidity and survival. Gynecol Oncol 2004; 93: 653-658.
11. Aapro MS, van Wijk FH, Bolis G et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: Definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 2003; 14: 441-448.
12. Fleming GF, Brunetto VL, Cella D et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgastrim in advanced endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 2004; 22: 2159-2166.
13. Randall ME, Brunetto G, Muss HB et al. Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: A randomized phase III trial of the Gynecologic Oncology Group. J Clin Oncol 2006; 24: 36-44.